The invention provides a combination therapy wherein one or more other therapeuticagents are administered with an organic arsenical, preferably SGLU-I or a pharmaceuticallyacceptable salt thereof. The invention also relates to methods for the treatmentof cancer, comprising administering SGLU-I in combination with another therapeuticagent. Another aspect of the invention relates to a kit comprising SGLU-I andanother therapeutic agent.